-       Report 
- August 2025
-  197 Pages 
- Global 
   From       €3156EUR$3,545USD£2,758GBP 
      €3507EUR$3,939USD£3,064GBP 
            -       Report 
- October 2025
-  193 Pages 
- Global 
   From       €3156EUR$3,545USD£2,758GBP 
      €3507EUR$3,939USD£3,064GBP 
          -       Report 
- October 2025
-  340 Pages 
- Global 
   From       €5208EUR$5,850USD£4,550GBP 
          -       Report 
- October 2025
-  250 Pages 
- Global 
   From       €3997EUR$4,490USD£3,493GBP 
          -       Report 
- October 2025
-  250 Pages 
- Global 
   From       €3997EUR$4,490USD£3,493GBP 
           -       Report 
- April 2025
-  200 Pages 
- Global 
   From       €3997EUR$4,490USD£3,493GBP 
          -       Report 
- March 2025
-  200 Pages 
- Global 
   From       €3997EUR$4,490USD£3,493GBP 
          -       Report 
- March 2025
-  175 Pages 
- Global 
   From       €3997EUR$4,490USD£3,493GBP 
          -       Drug Pipelines 
- June 2025
-  200 Pages 
- Global 
   From       €2483EUR$2,789USD£2,169GBP 
          -       Report 
- June 2025
-  131 Pages 
- Global 
   From       €13349EUR$14,995USD£11,664GBP 
            -       Report 
- August 2020
-  250 Pages 
- Saudi Arabia 
   From       €2564EUR$2,880USD£2,240GBP 
      €3205EUR$3,600USD£2,800GBP 
          -       Report 
- January 2024
-  200 Pages 
- Global 
   From       €3694EUR$4,150USD£3,228GBP 
          -       Report 
- February 2024
-  110 Pages 
- Global 
   From       €4228EUR$4,750USD£3,695GBP 
            -       Report 
- May 2024
-  139 Pages 
- Global 
   From       €4918EUR$5,524USD£4,297GBP 
      €5785EUR$6,499USD£5,055GBP 
          -       Report 
- July 2025
-  200 Pages 
- India 
   From       €2483EUR$2,789USD£2,169GBP 
          -       Report 
- August 2024
-  150 Pages 
- Global 
   From       €2483EUR$2,789USD£2,169GBP 
          -       Report 
- April 2023
-  91 Pages 
- Global 
   From       €3500EUR$4,212USD£3,165GBP 
          -       Report 
- October 2025
-  50 Pages 
- Global 
   From       €2359EUR$2,650USD£2,061GBP 
          -       Report 
- October 2025
-  50 Pages 
- Global 
   From       €2359EUR$2,650USD£2,061GBP 
       
      Pioglitazone is a drug used to treat type 2 diabetes, a condition in which the body does not produce enough insulin or does not use insulin properly. It belongs to a class of drugs known as thiazolidinediones, which work by increasing the body's sensitivity to insulin. Pioglitazone is used in combination with diet and exercise to improve glycemic control in adults with type 2 diabetes. It can also be used to reduce the risk of cardiovascular events in adults with type 2 diabetes and established    cardiovascular disease.
Pioglitazone is a widely used drug in the endocrine and metabolic disorders drug market. It is used to treat type 2 diabetes, a condition that affects millions of people worldwide. Pioglitazone is generally well tolerated and has been shown to improve glycemic control and reduce the risk of cardiovascular events in adults with type 2 diabetes.
Some companies in the pioglitazone market include Takeda Pharmaceuticals, Merck & Co., Sanofi, and Eli Lilly. Show Less   Read more